JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...

The 300TD now cranks up 9 more mph by the end of a quar­ter-mile and an additional 12 mph flat out (enough to vault the 100-mph hurdle). It's another one of those quantum leaps of tech­nology ...

WASHINGTON, United States (AFP) — United States President Donald Trump’s stop-start tariff rollout has “significantly” increased global financial stability risks, the International ...

James Quar McPherson Growing up in Jesmond, McPherson never progressed beyond United’s seconds (reserves) team. Serving as an Observer in the Royal Air Force Voluntary Reserve, he lost his life ...

DAKAR/TORONTO (Reuters) -A Malian judge is expected to order on Thursday the reopening of Barrick Mining's Loulo-Gounkoto gold mine under new management at the request of Mali's government, three ...

A glorious set of specialist troops that you could use for some intriguing This Quar's War scenarios, where perhaps you move away from the rank and file troops. This set comes with Trench Raiders, ...

FILIPINO tennis ace Alex Eala and world No. 3 Coco Gauff of the United States shoot for a quar-terfinals berth at the Italian Open women's doubles on Monday. Eala and Gauff take on the home bets Lisa ...

Lest we forget—welcome to this ANZAC day edition of Outside the Box, this week with news from Para Bellum Wargames, Puppetswar, Artel W Miniatures, Warlord Games, and more! New Founder’s and Artisan ...

Il­lu­mi­na es­ti­mates about $85 mil­lion in costs this year re­lat­ed to tar­iffs on its DNA se­quenc­ing prod­ucts, the com­pa­ny said Thurs­day dur­ing its quar­ter­ly earn ...

Pfiz­er, No­var­tis, Am­gen, Eli Lil­ly and John­son & John­son were the top con­gres­sion­al lob­by­ing spenders among the ma­jor bio­phar­ma com­pa­nies, as the in­dus­try ...